Develops novel therapies for the treatment of cancer, focusing on innovative approaches.
Rapport Therapeutics, Inc. is a forward-thinking clinical-stage biopharmaceutical company dedicated to pioneering the discovery and development of innovative small molecule therapies tailored for patients grappling with central nervous system (CNS) disorders. At the forefront of our research are neuronal receptors, intricate protein assemblies comprising principal subunits and receptor associated proteins (RAPs), which intricately regulate receptor expression and functionality.
Our lead product candidate, RAP-219, exemplifies our commitment to advancing neuroanatomically specific treatments by selectively targeting TARPg8, a critical RAP associated with neuronal AMPAR a validated therapeutic target in epilepsy. Having successfully completed Phase 1 trials evaluating RAP-219's safety and tolerability in healthy adults, we are poised to embark on a Phase 2a proof-of-concept trial in adults with drug-resistant focal epilepsy, with anticipated topline results in mid-2025.
Beyond epilepsy, we envision broader therapeutic applications for RAP-219, including potential benefits in managing peripheral neuropathic pain and bipolar disorder. Plans are underway to initiate Phase 2a trials in these indications by late 2024 and into 2025. Additionally, our pipeline includes RAP-199, an innovative molecule targeting TARPg8 with distinct chemical and pharmacokinetic properties, slated to enter Phase 1 trials in the first half of 2025. Rapport Therapeutics remains steadfast in its mission to redefine treatment paradigms and improve outcomes for patients grappling with CNS disorders through cutting-edge science and clinical innovation.